Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients

BACKGROUND: Extensive‐stage small cell lung cancer (ES‐SCLC) is deemed as a fatal malignancy with a poor prognosis. Although immunotherapy has gradually played an important role in the treatment of ES‐SCLC since 2018, ES‐SCLC treatment data and patient outcome before 2018, when chemotherapy served a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Li‐Ling, Hu, Xing‐Sheng, Wang, Yan, Li, Jun‐Ling, Wang, Hong‐Yu, Liu, Peng, Xu, Jian‐Ping, He, Xiao‐Hui, Hao, Xue‐Zhi, Jiang, Pei‐Di, Liu, Yu‐Tao, Luo, Jian, Zhou, Sheng‐Yu, Wang, Jin‐Wan, Yang, Jian‐Liang, Qin, Yan, Yuan, Peng, Lin, Lin, Shi, Yuan‐Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258353/
https://www.ncbi.nlm.nih.gov/pubmed/33969619
http://dx.doi.org/10.1111/1759-7714.13977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258353/
https://www.ncbi.nlm.nih.gov/pubmed/33969619
http://dx.doi.org/10.1111/1759-7714.13977

Ejemplares similares